Handbook of Hematologic Malignancies

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Notify me when this product is in stock

Handbook of Hematologic Malignancies

Third Edition

Editors

David A. Sallman, MD

Ateefa Chaudhury, MD

Hayder Saeed, MD

Ling Zhang, MD

Description

Handbook of Hematologic Malignancies 3^rd Edition remains an indispensable resource for busy hematologists, hematologic oncologists, hematopathologists, oncology advanced practice providers, oncology nurses, and trainees. This significantly revised and completely updated edition is meticulously organized to provide concise, essential information on diagnosis, prognosis, therapeutic management, and clinical trial opportunities for each hematologic malignancy. Each chapter features detailed figures that illustrate the hematopathologic characteristics of diseases, along with tables designed to simplify the review of differential diagnoses, prognostic scoring systems, molecular profiles, and therapeutic options.

This edition introduces a completely new set of challenging clinical cases, designed to rigorously test clinicians' knowledge of pathologic diagnosis and clinical presentation. With over 35 new FDA-approved indications since the second edition—featuring groundbreaking advancements such as CAR-T therapy—this handbook serves as a quick reference for practice-changing information on complex diagnostic dilemmas, frontline treatments, refractory scenarios, and relapse management. Purchase includes online access via most mobile devices or computers.

Key Features:

New chapters on precursor states in myeloid malignancies (CHIP/CCUS), familial/inherited risks of hematologic malignancies, CAR-T versus Bispecific Treatment, and mechanisms of CAR-T resistance.
Entirely new unfolding clinical cases with board-style questions, enhancing critical thinking and knowledge application with every clinical chapter.
Features updated chapters that concisely outline new standards of care and management considerations, accompanied by key references for further reading.
Highlights essential diagnostic tools, including updated 2022 WHO and ICC classification systems, that aid in conducting critical differential diagnoses and resolving complex diagnostic dilemmas.
Delivers key updates on potential practice-changing clinical trials and paradigm-shifting treatment considerations within each disease-based chapter, ensuring clinicians stay at the forefront of hematologic oncology.

Contents

Contributors

Preface

Abbreviations

PART I. INTRODUCTION AND OVERVIEW

1. Normal Hematopoiesis and Diagnosis Algorithms for Cytopenias and Cytoses

2. ICC and WHO Classifications and Potential Future Harmonization

3. Familial/Inherited Variants and Risks of Hematologic Malignancies

4. Diagnostic Approaches to Hematologic Malignancies

5. Minimal Residual Disease Assays

6. Personalized Approach to Hematologic Malignancies

PART II. MYELOPROLIFERATIVE NEOPLASMS

7. Polycythemia Vera

8. Essential Thrombocythemia

9. Primary Myelofibrosis

10. Chronic Myelogenous Leukemia

11. Chronic Neutrophilic Leukemia

12. Systemic Mastocytosis

13. Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion (MLN-TK)

PART III. MYELODYSPLASTIC AND BONE MARROW FAILURE SYNDROMES

14. CHIP, CCUS and Precursor States of Myeloid Neoplasms

15. Myelodysplastic Syndromes

16. Aplastic Anemia

17. Paroxysmal Nocturnal Hemoglobinuria

PART IV. MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS

18. Myelodysplastic/Myeloproliferative Neoplasms

19. Chronic Myelomonocytic Leukemia

PART V. ACUTE MYELOID LEUKEMIA AND RELATED SYNDROMES

20. Acute Myeloid Leukemia

21. Secondary AML and AML-MRC

22. Acute Promyelocytic Leukemia

23. Blastic Plasmacytoid Dendritic Cell Neoplasm

PART VI. ACUTE LYMPHOID LEUKEMIA

24. B-Lymphoblastic Leukemia/Lymphoma

25. BCR-ABL1+ B-Lymphoblastic Leukemia

26. T-Cell Acute Lymphoblastic Leukemia/Lymphoma

PART VII. ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE

27. Acute Leukemia of Ambiguous Lineage

PART VIII. MATURE T- AND NK-CELL LEUKEMIA

28. T-Cell Prolymphocytic Leukemia

29. T-Cell Large Granular Lymphocytic Leukemia

30. Aggressive Natural Killer Cell Leukemia

PART IX. PLASMA CELL DISORDERS

31. Monoclonal Gammopathy of Unknown Significance, Smoldering Myeloma, and Plasmacytomas

32. Multiple Myeloma

33. Waldenström Macroglobulinemia

34. Immunoglobulin Light Chain Amyloidosis AL

PART X. HODGKIN LYMPHOMA

35. Hodgkin Lymphoma

PART XI. NON-HODGKIN LYMPHOMA

36. Diagnosis and Classification of Non-Hodgkin Lymphomas

PART XII. MATURE B-CELL LYMPHOMA

VERY AGGRESIVE

37. Burkitt Lymphoma

AGGRESSIVE

38. Diffuse Large B-Cell Lymphoma

39. Double-Hit Lymphoma

40. Mantle Cell Lymphoma

41. Primary Central Nervous System Lymphoma

42. HIV-Related Lymphomas

43. Follicular Lymphoma

44. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

45. Hairy Cell Leukemia

46. Marginal Zone Lymphoma

PART XIII. MATURE T- AND NK-CELL LYMPHOMA

47. Peripheral T-Cell Lyphoma

48. Adult T-Cell Leukemia/Lymphoma

49. Anaplastic Large Cell Lymphoma

50. Extranodal Natural Killer/T-Cell Lymphoma

51. Mycosis Fungoides/Sézary Syndrome

52. Hepatosplenic T-Cell Lymphoma

PART XIV. HISTIOCYTIC/DENDRITIC CELL NEOPLASMS

53. Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Histiocytic Sarcoma

54. Hemophagocytic Lymphohistiocytosis

PART XV. BONE MARROW TRANSPLANTATION

55. Autologous Hematopoietic Cell Transplantation

56. Allogeneic Hematopoietic Cell Transplantation

PART XVI. NEW CELLULAR IMMUNOTHERAPY

57. CAR-T Overview and Novel Cellular Therapeutic Options

58. CD19 CAR T-Cell Therapy

59. BCMA CAR T-Cell Therapy

60. Cytokine Release Syndrome and Other Toxicities Associated With Cellular Therapies

PART XVII. EMERGENCIES IN HEMATOLOGY

61. Cancer-Associated Thrombosis in Hematologic Malignancies

62. Tumor Lysis Syndrome

63. Thrombotic Microangiopathy

64. Therapeutic Apheresis Indications

Appendix: Pathology Supplement

Index

Authors

David A. Sallman, MD, Associate Member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, University of South Florida Morsani College of Medicine, Tampa, Florida

Ateefa Chaudhury, MD, Hematologist, New Mexico Cancer Center, Albuquerque, New Mexico

Hayder Saeed, MD, Associate member, Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Ling Zhang, MD, Senior Member, Professor, Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida

Product Details